# Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)

> **NCT02051413** · PHASE4 · COMPLETED · sponsor: **Institut National de la Santé Et de la Recherche Médicale, France** · enrollment: 67 (actual)

## Conditions studied

- Major Depressive Disorder
- Major Depressive Episode

## Interventions

- **DRUG:** Venlafaxine extended release

## Key facts

- **NCT ID:** NCT02051413
- **Lead sponsor:** Institut National de la Santé Et de la Recherche Médicale, France
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-02-18
- **Primary completion:** 2018-05
- **Final completion:** 2018-05
- **Target enrollment:** 67 (ACTUAL)
- **Last updated:** 2025-09-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02051413

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02051413, "Beta-arrestins and Response to Venlafaxine in Major Depressive Disorder (MDD) (DEPARRESTCLIN)". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT02051413. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*